VYNE Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing differentiated therapies for the treatment of immuno-inflammatory conditions. Its product candidate is VYN201, a locally administered pan-BET inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, a BD2-selective oral small molecule bromodomain and extra-terminal (BET) inhibitor in preclinical development for the treatment of immuno-inflammatory indications. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.
成長中
同社は成長フェーズにあり、最新の年間収益はUSD 501.00Kに達しています。
高い利益成長
同社の純利益は業界をリードしており、最新の年間純利益はUSD 501.00Kです。
適正水準
同社の最新のPEは-0.36で、過去3年間の水準と比較して適正圏にあります。
機関投資家の売り越し
最新の機関投資家の保有株数は8.80M株で、前四半期比で6.25%減少しています。
バンガードが保有
スター投資家バンガードは本銘柄を496.30K株保有しています。
市場活動が活発
同社への投資家の関心が高まっており、20日間の売買回転率は2.76です。